Plus Therapeutics (PSTV) Common Equity (2010 - 2026)

Plus Therapeutics (PSTV) has 17 years of Common Equity data on file, last reported at $12.0 million in Q1 2026.

• Common Equity for Q1 2026 came in at $12.0 million, up 150.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.0 million (up 150.59% YoY), and the FY2025 annual result was $4.0 million, up 144.65% from the prior year.
• Common Equity improved to $12.0 million in Q1 2026 per PSTV's latest filing, from $4.0 million in the prior quarter.
• Over five years, Common Equity peaked at $14.6 million in Q1 2022 and troughed at -$23.6 million in Q1 2025.
• A 5-year average of $1.3 million and a median of $2.7 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 563.87% in 2024, then surged 197.68% in 2025.
• A 5-year view of Common Equity shows it stood at $6.4 million in 2022, then sank by 120.92% to -$1.3 million in 2023, then plunged by 563.87% to -$8.9 million in 2024, then jumped by 144.65% to $4.0 million in 2025, then jumped by 199.32% to $12.0 million in 2026.
• Business Quant data shows PSTV's Common Equity at $12.0 million in Q1 2026, $4.0 million in Q4 2025, and $5.1 million in Q3 2025.